Hologic (NASDAQ:HOLX) Releases FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 4.250-4.350 for the period, compared to the consensus estimate of 4.070. The company issued revenue guidance of $4.2 billion-$4.2 billion, compared to the consensus revenue estimate of $4.0 billion. Hologic also updated its FY25 guidance to $4.25-4.35 EPS.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $1.11 during midday trading on Thursday, hitting $79.38. 514,373 shares of the company’s stock were exchanged, compared to its average volume of 1,590,278. Hologic has a 12-month low of $66.93 and a 12-month high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The company has a market cap of $18.44 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 3.03 and a beta of 0.98. The business’s fifty day moving average price is $81.05 and its two-hundred day moving average price is $78.12.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 20.11% and a net margin of 19.59%. Hologic’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.89 earnings per share. As a group, research analysts forecast that Hologic will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HOLX. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Stephens restated an “overweight” rating and set a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.